The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
暂无分享,去创建一个
A. Rossi | A. Riccio | S. Piacentini | J. Rossignol | M. Santoro | Simone La Frazia | Silvia Santopolo | Silvia Pauciullo | Sara Piacentini | M. G. Santoro
[1] Haihong Zheng,et al. The modulation of metabolomics and antioxidant stress is involved in the effect of nitazoxanide against influenza A virus in vitro , 2023, Acta Virologica.
[2] William T. Harvey,et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness , 2023, Nature Reviews Microbiology.
[3] C. Bréchot,et al. Antiviral effect of thiazolides relies on mitochondrial mild uncoupling , 2022, bioRxiv.
[4] A. Adebiyi,et al. A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19 , 2022, Frontiers in Medicine.
[5] W. Venter,et al. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection , 2022, The Journal of antimicrobial chemotherapy.
[6] R. Nelli,et al. Human Air-Liquid-Interface Organotypic Airway Cultures Express Significantly More ACE2 Receptor Protein and Are More Susceptible to HCoV-NL63 Infection than Monolayer Cultures of Primary Respiratory Epithelial Cells , 2022, Microbiology spectrum.
[7] R. Baric,et al. Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms , 2022, Science Translational Medicine.
[8] P. Pelosi,et al. Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial , 2022, Frontiers in Medicine.
[9] B. Haagmans,et al. SARS-CoV-2 pathogenesis , 2022, Nature Reviews Microbiology.
[10] Reed J. D. Sorensen,et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.
[11] C. Bréchot,et al. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 , 2022, eClinicalMedicine.
[12] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[13] J. V. Falvo,et al. The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters , 2022, bioRxiv.
[14] Xiaoping Zhou,et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis , 2022, Annals of medicine.
[15] X. de Lamballerie,et al. Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 , 2021, bioRxiv.
[16] J. Butterton,et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.
[17] Jincun Zhao,et al. Two novel human coronavirus OC43 genotypes circulating in hospitalized children with pneumonia in China , 2021, Emerging microbes & infections.
[18] M. C. Muenker,et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2021, Nature Communications.
[19] Fangfang Zhou,et al. The way of SARS-CoV-2 vaccine development: success and challenges , 2021, Signal Transduction and Targeted Therapy.
[20] P. O’Neill,et al. Synthesis, antiviral activity, preliminary pharmacokinetics and structural parameters of thiazolide amine salts. , 2021, Future medicinal chemistry.
[21] R. Diaz,et al. Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial. , 2021, EClinicalMedicine.
[22] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[23] A. Rossi,et al. Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence , 2021, Cellular and Molecular Life Sciences.
[24] M. Thompson,et al. Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. , 2021, medRxiv.
[25] H. Mouquet,et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.
[26] Lisa E. Gralinski,et al. SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801 , 2021, Nature.
[27] M. Santoro,et al. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy , 2020, Biochemical and Biophysical Research Communications.
[28] E. Carafoli,et al. Remdesivir: From Ebola to COVID-19 , 2020, Biochemical and Biophysical Research Communications.
[29] P. Pelosi,et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial , 2020, European Respiratory Journal.
[30] M. Diamond,et al. JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis , 2020, bioRxiv.
[31] H. Goossens,et al. Seasonal coronavirus protective immunity is short-lasting , 2020, Nature Medicine.
[32] P. Wark,et al. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells , 2020, American journal of physiology. Lung cellular and molecular physiology.
[33] E. Chevet,et al. Role of the early secretory pathway in SARS-CoV-2 infection , 2020, The Journal of cell biology.
[34] A. Rossi,et al. The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction , 2020, Cellular and Molecular Life Sciences.
[35] Qi Cheng,et al. Infectivity of human coronavirus in the brain , 2020, EBioMedicine.
[36] T. Fung,et al. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae) , 2020, Reference Module in Life Sciences.
[37] Xiang Li,et al. On the origin and continuing evolution of SARS-CoV-2 , 2020, National science review.
[38] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[39] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[40] Chunmei Wang,et al. Tizoxanide induces autophagy by inhibiting PI3K/Akt/mTOR pathway in RAW264.7 macrophage cells , 2020, Archives of Pharmacal Research.
[41] A. Rossi,et al. The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2 , 2019, Molecular Cancer Research.
[42] T. Fung,et al. Human Coronavirus: Host-Pathogen Interaction. , 2019, Annual review of microbiology.
[43] S. Bavari,et al. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus , 2019, iScience.
[44] Zhènglì Shí,et al. Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.
[45] Kai-Li Wang,et al. Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma , 2018, Cell Death & Disease.
[46] A. Riccio,et al. The second‐generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication , 2018, Antiviral research.
[47] J. Pedersen,et al. Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57 , 2018, Scientific Reports.
[48] E. Trotta,et al. Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance , 2017, Proceedings of the National Academy of Sciences.
[49] Fang Li,et al. Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.
[50] T. Jacques,et al. Human Coronavirus OC43 Associated with Fatal Encephalitis. , 2016, The New England journal of medicine.
[51] J. Tam,et al. Human Coronaviruses: A Review of Virus–Host Interactions , 2016, Diseases.
[52] Minhee Kang,et al. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. , 2016, AIDS research and human retroviruses.
[53] M. Clerici,et al. Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication , 2016, Scientific Reports.
[54] J. Rossignol,et al. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus , 2016, Journal of Infection and Public Health.
[55] Chengchao Xu,et al. Glycosylation-directed quality control of protein folding , 2015, Nature Reviews Molecular Cell Biology.
[56] C. Amici,et al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR , 2015, Cellular microbiology.
[57] L. Montaner,et al. Short communication: Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. , 2015, AIDS research and human retroviruses.
[58] O. Cenciarelli,et al. Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro , 2014, Antimicrobial Agents and Chemotherapy.
[59] Xuming Zhang,et al. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs , 2014, Antiviral Research.
[60] K. Pyrć,et al. Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells , 2014, Journal of Virology.
[61] J. Rossignol. Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.
[62] T. Butters,et al. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores. , 2014, Virology.
[63] C. Ginocchio,et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial , 2014, The Lancet Infectious Diseases.
[64] K. Nakagaki,et al. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease , 2014, Journal of medical virology.
[65] A. Ciucci,et al. Thiazolides, a New Class of Antiviral Agents Effective against Rotavirus Infection, Target Viral Morphogenesis, Inhibiting Viroplasm Formation , 2013, Journal of Virology.
[66] Karen K. Y. Lam,et al. Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis , 2012, PLoS pathogens.
[67] T. Vesikari,et al. Detection of human coronaviruses in children with acute gastroenteritis , 2010, Journal of Clinical Virology.
[68] J. Puglisi,et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. , 2009, Gastroenterology.
[69] A. Ciucci,et al. Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level* , 2009, The Journal of Biological Chemistry.
[70] K. Nichol,et al. Human Coronavirus and Acute Respiratory Illness in Older Adults with Chronic Obstructive Pulmonary Disease , 2009, The Journal of infectious diseases.
[71] E. Keeffe,et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. , 2009, Gastroenterology.
[72] A. Ciucci,et al. Thiazolides: A New Class of Broad-Spectrum Antiviral Drugs Targeting Virus Maturation , 2007, Antiviral Research.
[73] M. Santoro,et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial , 2006, The Lancet.
[74] B. Berkhout,et al. Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle , 2006, Antimicrobial Agents and Chemotherapy.
[75] G. Almazan,et al. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice , 2006, Virology.
[76] J. Rossignol,et al. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[77] S. Stohlman,et al. Coronavirus infection of the central nervous system: host–virus stand-off , 2006, Nature Reviews Microbiology.
[78] P. Maes,et al. Development of One-Step, Real-Time, Quantitative Reverse Transcriptase PCR Assays for Absolute Quantitation of Human Coronaviruses OC43 and 229E , 2005, Journal of Clinical Microbiology.
[79] Y. Guan,et al. Human Coronavirus NL63 Infection and Other Coronavirus Infections in Children Hospitalized with Acute Respiratory Disease in Hong Kong, China , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[80] E. Shapiro,et al. Association between a Novel Human Coronavirus and Kawasaki Disease , 2005, The Journal of infectious diseases.
[81] Samson S. Y. Wong,et al. Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia , 2005, Journal of Virology.
[82] B. Berkhout,et al. Identification of a new human coronavirus , 2004, Nature Medicine.
[83] A. Cariou,et al. Coronavirus 229E-Related Pneumonia in Immunocompromised Patients , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[84] J. Rossignol,et al. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. , 2001, The Journal of infectious diseases.
[85] J. Newcombe,et al. Neuroinvasion by Human Respiratory Coronaviruses , 2000, Journal of Virology.
[86] F. Chagnon,et al. Persistent Infection of Human Oligodendrocytic and Neuroglial Cell Lines by Human Coronavirus 229E , 1999, Journal of Virology.
[87] P. Talbot,et al. Acute and Persistent Infection of Human Neural Cell Lines by Human Coronavirus OC43 , 1999, Journal of Virology.
[88] H. Klenk,et al. Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity , 1997, Journal of virology.
[89] M. Pagano,et al. Student's t test. , 1993, Nutrition.
[90] C. Amici,et al. Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. , 1989, The Journal of general virology.
[91] M. Esteban,et al. Antiviral effect of prostaglandins of the A series: inhibition of vaccinia virus replication in cultured cells. , 1982, The Journal of general virology.
[92] D. Hamre,et al. A New Virus Isolated from the Human Respiratory Tract.∗ , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[93] D. Tyrrell,et al. Cultivation of a Novel Type of Common-cold Virus in Organ Cultures , 1965, British medical journal.
[94] B. Korba,et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. , 2008, Antiviral research.
[95] M. Esteban,et al. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus , 2005, Archives of Virology.